WO1995005454A1 - Bacteriophages mis au point par genie genetique et vaccins les contenant - Google Patents
Bacteriophages mis au point par genie genetique et vaccins les contenant Download PDFInfo
- Publication number
- WO1995005454A1 WO1995005454A1 PCT/GB1994/001827 GB9401827W WO9505454A1 WO 1995005454 A1 WO1995005454 A1 WO 1995005454A1 GB 9401827 W GB9401827 W GB 9401827W WO 9505454 A1 WO9505454 A1 WO 9505454A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- bacteriophage
- phage
- protein
- peptide
- hybrid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
- C07K14/445—Plasmodium
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
- C07K14/675—Beta-endorphins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32111—Aphthovirus, e.g. footandmouth disease virus
- C12N2770/32121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32111—Aphthovirus, e.g. footandmouth disease virus
- C12N2770/32122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Definitions
- This invention relates to engineered bacteriophage and vaccines containing them. Background of the Invention
- Figure 1 is a schematic view of a hybrid filamentous bacteriophage. It shows a gene III protein 1, a coat protein with epitope 2, a wild-type coat protein 3, and an epitope 4 that is too large for normal packing of subunits.
- Epitope libraries allow large numbers (sometimes tens of millions) of small peptides to be surveyed for any desirable property, e.g. tight binding to an antibody, receptor or other binding protein.
- An epitope library can be used to find the antigenic target of the antibodies, hence identifying the physiological site of the disease and suggesting a route for therapeutic procedures. It may also be possible to discover peptides which mimic the biologically-active regions of hormones, cytokines, enzyme substrates, neuropeptides and other bio olecules. Peptides which could either replace or alter the action of the natural ligands would be powerful candidates for drug development.
- the hybrid hage allows the number of copies of a peptide displayed on each viral particle to be controlled within wide limits, and can confer great sensitivity.
- hybrid MN phage (2 ⁇ g/well) or hybrid MN phage and wild-type phage fd (20 ⁇ g/well) .
- the hybrid MN phage is equivalent to 1 ⁇ g peptide/well.
- the peptides were: 12-mer, IHIGPGRAFYTT; 23- mer, YNKRKRIHIGPGRAFYTTKNIIG.
- Sequence Type Nucleotide Sequence Length: 18 bases Strandedness: Single Topology: Linear GGGATCGTTA ACCTCAGC
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Crystallography & Structural Chemistry (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
On a mis au point par génie génétique un bactériophage filamenteux permettant de faire apparaître des épitopes des lymphocytes T et des épitopes des lymphocytes B et/ou un peptide capable de produire des anticorps neutralisant le VIH. On a pu ainsi observer une immunogénicité efficace.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US95832192A | 1992-02-22 | 1992-02-22 | |
GB9317304.5 | 1993-08-19 | ||
GB939317304A GB9317304D0 (en) | 1993-08-19 | 1993-08-19 | Engineered bacteriophages and their use |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1995005454A1 true WO1995005454A1 (fr) | 1995-02-23 |
Family
ID=26303401
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB1994/001827 WO1995005454A1 (fr) | 1992-02-22 | 1994-08-19 | Bacteriophages mis au point par genie genetique et vaccins les contenant |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO1995005454A1 (fr) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1088889A1 (fr) * | 1999-10-01 | 2001-04-04 | University Of Cambridge | Bactériophage filamenteux double-hybride recombinant |
GB2370770B (en) * | 2001-01-03 | 2005-06-01 | Simon Connolly | Uses of Streptococcus Vaccines |
EP1729799A2 (fr) * | 2004-01-09 | 2006-12-13 | Kary B. Mullis | Immunite programmable chimiquement |
US7232564B2 (en) | 2001-07-18 | 2007-06-19 | Instytut Immunologii I Terapii Doswiadczal-Nej Pan | Methods of polyvalent bacteriophage preparation for the treatment of bacterial infections |
WO2010036132A1 (fr) | 2008-09-29 | 2010-04-01 | Instytut Immunologii i Terapii Doświadczalnej PAN | Nouvelles souches de bactériophage pour le traitement d’infections bactériennes, en particulier des souches pharmacorésistantes du genre enterococcus |
US7850975B2 (en) | 1999-12-22 | 2010-12-14 | Altermune Technologies, Llc | Chemically programmable immunity |
WO2011162626A1 (fr) | 2010-06-20 | 2011-12-29 | Instytut Immunologii i Terapii Doświadczalnej PAN | Nouvelles souches de bactériophages pour le traitement d'infections bactériennes, en particulier par des souches de bactéries pharmacorésistantes du genre stenotrophomonas |
US8604184B2 (en) | 2009-05-05 | 2013-12-10 | The United States Of America As Represented By The Secretary Of The Air Force | Chemically programmable immunity |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0429816A1 (fr) * | 1989-10-31 | 1991-06-05 | F. Hoffmann-La Roche Ag | Composition de vaccin à base d'un épitope non-immunosuppressif de cellules T |
WO1992007077A1 (fr) * | 1990-10-12 | 1992-04-30 | Cambridge Bacteriophage Technologies Limited | Bacteriophages modifies par genie genetique et vaccins les contenant |
GB2253626A (en) * | 1991-01-24 | 1992-09-16 | British Tech Group | Antigen-presenting chimaeric protein |
-
1994
- 1994-08-19 WO PCT/GB1994/001827 patent/WO1995005454A1/fr active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0429816A1 (fr) * | 1989-10-31 | 1991-06-05 | F. Hoffmann-La Roche Ag | Composition de vaccin à base d'un épitope non-immunosuppressif de cellules T |
WO1992007077A1 (fr) * | 1990-10-12 | 1992-04-30 | Cambridge Bacteriophage Technologies Limited | Bacteriophages modifies par genie genetique et vaccins les contenant |
GB2253626A (en) * | 1991-01-24 | 1992-09-16 | British Tech Group | Antigen-presenting chimaeric protein |
Non-Patent Citations (6)
Title |
---|
ANNE E. WILLIS ET AL: "Immunological properties of foreign peptides in multiple display on a filamentous bacteriophage", GENE, vol. 128, 1993 * |
DANI P. BOLOGNESI: "HIV antibodies and vaccine design", AIDS, vol. 3, no. 1, 1989 * |
Dialog Information Service, file 154, Medline, Dialog accession No. 06508754, Medline accession No. 88153754, de la Cruz VF et al: "Immunogenicity and *epitope* mapping of foreign sequences via genetically engineered filamentous phage", J Biol Chem (UNITED STATES) Mar 25 1988, 263 (9) p 4318-22 * |
National Library of Medicine (NLM), file Medline, Medline accession no. 93212503, Keller PM: "Identification of HIV vaccine candidate peptides by screening random phage epitope libraries", Virology 1993 Apr; 193(2):709-16 * |
O.O. MINENKOVA ET AL: "Design of specific immunogens using filamentous phage as the carrier", GENE, vol. 128, 1993, XP023539031, DOI: doi:10.1016/0378-1119(93)90157-X * |
R.L. WARREN ET AL: "Method for identifying microbial antigens that stimulate specific lymphocyte responses: Application to Salmonella", PROC. NATL. ACAD. SCI, vol. 87, 1990, USA * |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001025416A1 (fr) * | 1999-10-01 | 2001-04-12 | University Of Cambridge | Bacteriophage filamenteux double-hybride recombinant |
EP1088889A1 (fr) * | 1999-10-01 | 2001-04-04 | University Of Cambridge | Bactériophage filamenteux double-hybride recombinant |
US8236321B2 (en) | 1999-12-22 | 2012-08-07 | Altermune Technologies, Llc | Chemically programmable immunity |
US8591910B2 (en) | 1999-12-22 | 2013-11-26 | Altermune Technologies Llc | Chemically programmable immunity |
US7645743B2 (en) | 1999-12-22 | 2010-01-12 | Altermune, Llc | Chemically programmable immunity |
US8263082B2 (en) | 1999-12-22 | 2012-09-11 | Altermune Technologies Llc | Chemically programmable immunity |
US7850975B2 (en) | 1999-12-22 | 2010-12-14 | Altermune Technologies, Llc | Chemically programmable immunity |
GB2370770B (en) * | 2001-01-03 | 2005-06-01 | Simon Connolly | Uses of Streptococcus Vaccines |
US7232564B2 (en) | 2001-07-18 | 2007-06-19 | Instytut Immunologii I Terapii Doswiadczal-Nej Pan | Methods of polyvalent bacteriophage preparation for the treatment of bacterial infections |
EP1729799A2 (fr) * | 2004-01-09 | 2006-12-13 | Kary B. Mullis | Immunite programmable chimiquement |
EP1729799A4 (fr) * | 2004-01-09 | 2008-11-05 | Kary B Mullis | Immunite programmable chimiquement |
WO2010036132A1 (fr) | 2008-09-29 | 2010-04-01 | Instytut Immunologii i Terapii Doświadczalnej PAN | Nouvelles souches de bactériophage pour le traitement d’infections bactériennes, en particulier des souches pharmacorésistantes du genre enterococcus |
US8604184B2 (en) | 2009-05-05 | 2013-12-10 | The United States Of America As Represented By The Secretary Of The Air Force | Chemically programmable immunity |
WO2011162626A1 (fr) | 2010-06-20 | 2011-12-29 | Instytut Immunologii i Terapii Doświadczalnej PAN | Nouvelles souches de bactériophages pour le traitement d'infections bactériennes, en particulier par des souches de bactéries pharmacorésistantes du genre stenotrophomonas |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0552267B1 (fr) | Bacteriophages modifies par genie genetique et vaccins les contenant | |
EP0572433B1 (fr) | Capside presentant un antigene, avec une proteine enveloppe de ms2 de fusion | |
JP3851938B2 (ja) | 植物、動物、およびヒトのワクチンとして並びに免疫療法に有用な抗体の免疫優性エピトープの弱化 | |
Keller et al. | Identification of HIV vaccine candidate peptides by screening random phage epitope libraries | |
CA2170412C (fr) | Virus de vegetaux modifies utilise, en tant que vecteurs de peptides heterologues | |
RU2201421C2 (ru) | Синтетический пептид hiv (варианты), иммуногенная композиция для индукции иммунного ответа против пептидов hiv, диагностический набор для определения hiv-специфичных антител | |
Nardelli et al. | A chemically defined synthetic vaccine model for HIV-1. | |
HRP970092A2 (en) | Synthetic hiv genes | |
EP1098910A1 (fr) | Complexe antigenique comprenant un peptide immunostimulateur, cd4 et un domaine de recepteur de chemokine pour traiter vih et des maladies immunitaires | |
EP0787139B1 (fr) | Peptides de synthese et vaccins les contenant | |
CA2084180A1 (fr) | Expression d'immunogenes specifiques a l'aide d'antigenes viraux | |
JP2006020635A (ja) | 抗原的に標識した非感染性レトロウィルス様粒子 | |
JPH04502760A (ja) | エイズの診断,予防および治療に有効な新規hiv蛋白質およびペプチド | |
WO1994018234A1 (fr) | Obtention de proteines de recombinaison contenant des determinants antigeniques multiples lies par des domaines d'articulation souples | |
WO1995005454A1 (fr) | Bacteriophages mis au point par genie genetique et vaccins les contenant | |
EP0651806B1 (fr) | Vaccins contre le virus de l'immunodeficience anti-feline (vif) | |
EP0728015B1 (fr) | Procede de preparation d'un set d' antigenes polypeptidiques combinatoires | |
EP0322394A2 (fr) | Expression des protéines de HIV dans E.coli et S.cerevisiae | |
JPS63254983A (ja) | エイズの病原であるウイルスのp25蛋白質をコードするウイルスベクター及び組換DNA、感染された細胞培養物、得られる蛋白質、ワクチン及び得られる抗体 | |
US20060275309A1 (en) | Peptide oligomers for use as hiv vaccines | |
Boudet et al. | Fine analysis of immunoreactivity of V3 peptides: antibodies specific for V3 domain of laboratory HIV type 1 strains recognize multiple V3 sequences synthesized from field HIV type 1 isolates | |
PH26855A (en) | Vaccines against acquired immune deficiency syndrome |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
ENP | Entry into the national phase |
Ref country code: US Ref document number: 1996 604958 Date of ref document: 19960603 Kind code of ref document: A Format of ref document f/p: F |
|
122 | Ep: pct application non-entry in european phase |